Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · Real-Time Price · USD
1.050
-0.020 (-1.87%)
Nov 21, 2024, 10:50 AM EST - Market open

Company Description

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors.

Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.

It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021.

Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Achilles Therapeutics plc
Achilles Therapeutics logo
Country United Kingdom
Founded 2016
IPO Date Mar 31, 2021
Industry Biotechnology
Sector Healthcare
Employees 215
CEO Iraj Ali

Contact Details

Address:
245 Hammersmith Road
London, W6 8PW
United Kingdom
Phone 44 20 8154 4600
Website achillestx.com

Stock Details

Ticker Symbol ACHL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001830749
CUSIP Number 00449L102
ISIN Number US00449L1026
SIC Code 2836

Key Executives

Name Position
Dr. Iraj Ali Ph.D. Chief Executive Officer and Director
Dr. Sergio A. Quezada Ph.D. Founder and Chief Scientific Officer
Robert Coutts Chief Financial Officer
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Founder and Member of Scientific Advisory Board
Dr. Charles Swanton FMEDSCI, M.D., Ph.D. Founder and Member of Scientific Advisory Board
Lee M. Stern Vice President of Investor Relations and External Communications
Daniel Carey Cazel Hood General Counsel and Company Secretary
Julia Wilson Head of Communications
Tariq Ahmed Executive Vice President of People
Edward Samuel Executive Vice President of Technical Operations

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 6-K Report of foreign issuer
Sep 25, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 19, 2024 6-K Report of foreign issuer
Aug 14, 2024 6-K Report of foreign issuer
Aug 5, 2024 6-K Report of foreign issuer
Jun 27, 2024 6-K Report of foreign issuer
May 24, 2024 6-K Report of foreign issuer
May 17, 2024 6-K Report of foreign issuer
May 8, 2024 6-K Report of foreign issuer